Premium
[P4–008]: QUALITY ASPECTS OF A NOVEL COGNITIVE‐FUNCTIONAL COMPOSITE FOR THE MEASUREMENT OF DISEASE PROGRESSION IN ALZHEIMER's DISEASE: FEASIBILITY, TEST‐RETEST RELIABILITY AND PRACTICE EFFECTS
Author(s) -
Jutten Roos J.,
Harrison John,
Lee Meeuw Kjoe Philippe,
Jan de Jong Frank,
Aleman André,
Ritchie Craig W.,
Scheltens Philip,
Sikkes Sietske A.M.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.1872
Subject(s) - verbal fluency test , intraclass correlation , audiology , psychology , dementia , cognition , recall , digit symbol substitution test , memory span , episodic memory , trail making test , medicine , clinical psychology , neuropsychology , working memory , psychometrics , disease , psychiatry , cognitive psychology , pathology , alternative medicine , placebo
positive allosteric modulator (PAM) to establish functional biomarkers of central target engagement in healthy young adults. Conclusions: Together with safety measures, these novel cognitive biomarkers used in Phase 1/2 POC studies show promise to help establish the dose range to be used in future clinical studies aimed at improving cognitive function in AD and may also be useful as functional biomarkers for Phase 3 clinical trials.